Otsuka Holdings Co. (OTSKY) 16.8900 $OTSKY
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - 22 Drug Profiles from 11 Companies
M2 - Fri Sep 12, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c97xhn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Santen Pharmaceutical Co., Ltd. - Oxford BioMedica plc - Sylentis S.A. - Ono Pharmaceutical Co., Ltd. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Amakem NV Drug Profiles - tafluprost - (tafluprost timolol maleate) - latanoprostene bunod - latanoprost - OPC-1085EL - trabodenoson - SYL-040012 - RO-5093151 - latanoprost - AR-13324 - AMA-0076 - ONO-9054 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - latanoprost SR - Glaucoma-GT - ATS-8535 - Small Molecule for Glaucoma For more information visit http://www.researchandmarkets.com/research/c97xhn/openangle
Global Chronic Heart Failure Therapeutics Pipeline Review 2014 - 21 Companies & 31 Drug Profiles
M2 - Thu Sep 11, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wx7flm/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Amgen Inc. - Sanofi - Novartis AG - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Pfizer Inc. - Bayer AG - Celladon Corporation - Mesoblast Limited - Palatin Technologies, Inc. - AnGes MG, Inc. - MetrioPharm AG - Cyano Biotech GmbH - NormOxys, Inc. - Cardioxyl Pharmaceuticals, Inc. - PhaseBio Pharmaceuticals, Inc. - miRagen Therapeutics, Inc. - Fibrotech Therapeutics Pty. Ltd. - Otsuka Holdings Co., Ltd. - Zensun (Shanghai) Sci & Tech Co., Ltd. Drug Profiles - Neucardin - rivaroxaban - (sacubitril valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - ivabradine - PL-3994 - omecamtiv mecarbil - Mydicar - CXL-1020 - serelaxin (recombinant) - tolvaptan - finerenone - ivabradine - F-373280 - Stem Cell Therapy for Cardiovascular Diseases - cenderitide - beperminogene perplasmid - OXY-111A - Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - MGN-9103 - BR-5489 - FT-011 - PB-1046 - Cell Therapy for Chronic Heart Failure - SAR-296968 - RNAi Gene Therapy to Inhibit STIM1 for Cardiovascular Diseases - Peptides Inhibiting ACE for Cardiovascular and Metabolic Disorders - Vestiras For more information visit http://www.researchandmarkets.com/research/wx...onic_heart
Polycystic Kidney Disease Therapeutics Pipeline Review, H2 2014 - 21 Drug Profiles from 11 Companies
M2 - Tue Sep 09, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8mqd9t/polycystic_kidney) has announced the addition of the "Polycystic Kidney Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycystic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Plexxikon Inc. - Ipsen S.A. - Pfizer Inc. - Synta Pharmaceuticals Corp. - Metabolic Solutions Development Company, LLC - IC-MedTech, Inc. - Endocyte, Inc. - ManRos Therapeutics - DiscoveryBiomed, Inc. - Otsuka Holdings Co., Ltd. - Kadmon Corporation, LLC Drug Profiles - tolvaptan - tolvaptan - lanreotide acetate - bosutinib - KD-020 - KD-019 - GLG-302 (ascorbic acid menadione) - MSDC-0160 - MSDC-0602 - EC-0371 - Small Molecule to Inhibit CKD for Polycystic Kidney Disease - Small Molecule to Inhibit Raf Kinase for Polycystic Kidney Disease - STA-2842 - Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Small Molecules to Activate AMPK for Polycystic Kidney Disease - Small Molecule to Inhibit EnaC for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Small Molecule for Polycystic Kidney Disease - Drugs Targeting CIL-1 for Genetic Disorders and Polycystic Kidney Disease - Drugs for Polycystic Kidney Disease - Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders - pyrimethamine For more information visit http://www.researchandmarkets.com/research/8m...tic_kidney
Atrial Fibrillation - Pipeline Review Report, H2 2014 - 15 Companies & 27 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xr5nbq/atrial) has announced the addition of the "Atrial Fibrillation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - AstraZeneca PLC - Isis Pharmaceuticals, Inc. - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Nissan Chemical Industries, Ltd. - Laboratoires Pierre Fabre SA - Cardiome Pharma Corp - Xention Limited - HUYA Bioscience International, LLC - Milestone Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Serodus ASA - Nyken BV - Armetheon, Inc. Drug Profiles - edoxaban tosylate - tecarfarin - vernakalant hydrochloride - bucindolol hydrochloride - vernakalant hydrochloride - ranolazine ER - XEN-D0103 - HBI-3000 - ISIS-CRPRx - (ranolazine dronedarone) - vanoxerine - F-373280 - BMS-919373 - XEN-D0101 - OPC-108459 - budiodarone - Small Molecule to Inhibit IKACh for Atrial Fibrillation - MSP-2017 - NYK-1112 - SER-102 - XEN-R0702 - GsMTx-4 - NIP-151 - Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug For Atrial Fibrillation - Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation - Small Molecules to Inhibit Voltage Gated Sodium Channel for Atrial Fibrillation For more information visit http://www.researchandmarkets.com/research/xr5nbq/atrial
Dementia Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pmw68m/dementia) has announced the addition of the "Dementia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Dementia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dementia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Dementia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Sylentis S.A. - FORUM Pharmaceuticals Inc. - Ildong Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - WhanIn Pharmaceutical Co., Ltd. - Hyundai Pharmaceutical Co., Ltd. - Summit Corporation plc - Oryzon Genomics S.A. - Intellect Neurosciences, Inc. - Intra-Cellular Therapies, Inc. - Tautatis Incorporated - Pacific Northwest Biotechnology, LLC - Otsuka Holdings Co., Ltd. - Chase Pharmaceuticals Corporation - Echo Pharmaceuticals B.V. - Chronos Therapeutics Limited - Alector LLC - ImStar Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/pmw68m/dementia
Global Glaucoma Therapeutics Market Forecasts & Opportunities, 2018
M2 - Wed Jul 02, 2:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zpvs7l/global_glaucoma) has announced the addition of the "Global Glaucoma Therapeutics Market Forecasts & Opportunities, 2018" report to their offering. Glaucoma is a disease of the eye in which fluid pressure within the eye increases. If left untreated the patient may lose vision and even become blind. The exact etiology of optic nerve damage due to glaucoma is not fully known, but involves mechanical compression and/or decreased blood flow in the optic nerve. Based on whether the cause of the disease is unknown or known, glaucoma is divided into two types, open angle and closed angle glaucoma. Five main classes of medical treatment are currently used to lower intraocular pressure: prostaglandins, beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, and fixed dose combinations. The Global Glaucoma Therapeutics market can be divided into five segments: Prostaglandins, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, and Fixed Dose Combinations. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Glaucoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Allergan Inc. - Merck & Co. Inc. - Novartis AG - Pfizer Inc. Other Prominent Vendors - Acadia Pharmaceuticals Inc. - AC Immune SA - Acorn Biomedical Inc. - Advanced Cell Technology Inc. - Aerie Pharmaceuticals Inc. - Carl Zeiss Meditec Inc. - Falcon Pharmaceuticals Ltd. - Inotek Pharmaceuticals Corp. - Lexicon Pharmaceuticals Inc. - Neurotech Pharmaceuticals Inc. - NicOx SA - Otsuka Holdings Co. Ltd. - Phytopharm plc - Santen Pharmaceuticals Co. Ltd. - Senju Pharmaceutical Co. Ltd. - SIFI SpA - Valeant Pharmaceuticals International Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Pipeline Snapshot - Rate of Incidence and Prevalence - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zp...l_glaucoma
Autism - Pipeline Review, H1 2014 - 20 Companies & 42 Drug Profiles
M2 - Fri Jun 20, 2:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ltzhjv/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - Merz Pharma GmbH & Co. KgaA - Teva Pharmaceutical Industries Limited - Avanir Pharmaceuticals, Inc. - Snowdon Inc. - Curemark, LLC - Coronado Biosciences, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Cellceutix Corporation - Heptares Therapeutics Ltd. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Naurex, Inc. - Nectid, Inc. - Mnemosyne Pharmaceuticals, Inc. - BioCrea GmbH - Saniona AB Drug Profiles - CM-AT - lurasidone hydrochloride - aripiprazole - cycloserine - fluoxetine - oxytocin - oxytocin - memantine hydrochloride - TSO - pioglitazone hydrochloride - oxytocin - oxytocin - (dextromethorphan hydrobromide quinidine sulfate) - oxytocin - oxytocin - RG-7314 - fluoxetine - fluoxetine - argipressin tannate - NU-211-01 NC-215-01 - Autologous Hematopoietic Stem Cells - glatiramer acetate - ITI-007 - Stem Cell Therapy for Central Nervous System Disorders - KM-391 - Program For Neurological Disorders - STX-110 - CN-2097 - acamprosate calcium - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome For more information visit http://www.researchandmarkets.com/research/lt...m_pipeline
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014: 16 Companies & 27 Drugs Profiled
M2 - Thu Jun 19, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhf5zs/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Nanotherapeutics, Inc. - Neurocrine Biosciences, Inc. - Addex Therapeutics - Neuralstem, Inc. - Catalyst Pharmaceutical Partners, Inc. - Humanetics Corporation - NeuroNascent, Inc. - Azevan Pharmaceuticals, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Vanda Pharmaceuticals Inc. - Marinus Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Tonix Pharmaceuticals Holding Corp. - Sage Therapeutics - Istituto Italiano di Tecnologia Drug Profiles - brexpiprazole - PRX-3140 - verucerfont - atorvastatin calcium - aprepitant - ganaxolone - iloperidone - mifepristone - oxytocin - 7-Keto - SRX-251 - SRX-246 - ITI-007 - NNI-351 - mGluR7-NAM Program For Central Nervous System Disorders - NSI-189 - cyclobenzaprine hydrochloride - S-107 - Small Molecule Targeting GABAA Receptor For Post Traumatic Stress Disorder - ZL-006 - ADX-71743 - Dihydroxyflavone - TLR-4 Antagonists for CNS Disorders - Immune Therapy For PTSD and Depression - Small Molecule Targeting GPR83 for CNS and Autoimmune Disorders - Small Molecules to Inhibit FAAH for CNS Disorders - vigabatrin For more information visit http://www.researchandmarkets.com/research/hh...ttraumatic
Global Autism Clinical Trials Review 2014
M2 - Tue Jun 17, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhfbw6/autism_global) has announced the addition of the "Autism Global Clinical Trials Review, H1, 2014" report to their offering. Autism Global Clinical Trials Review, H1, 2014 provides data on the Autism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Autism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Autism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Autism Speaks, Inc. - Seaside Therapeutics, LLC - Forest Laboratories, Inc. - Johnson & Johnson - Otsuka Holdings Co., Ltd. - F. Hoffmann-La Roche Ltd. - Bristol-Myers Squibb Company - Coronado Biosciences, Inc. - ZonMw - Dainippon Sumitomo Pharma Co., Ltd. - National Institute of Mental Health - Massachusetts General Hospital - Tehran University of Medical Sciences - Eunice Kennedy Shriver National Institute of Child Health and Human Development - Hugo W. Moser Research Institute at Kennedy Krieger, Inc. - Stanford University - The University of Hong Kong - University of California, Los Angeles - Mount Sinai Hospital - University of California, San Francisco For more information visit http://www.researchandmarkets.com/research/vh...ism_global
Ocular Hypertension - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bzfhkc/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Allergan, Inc. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. - Kowa Company, Ltd. - Ono Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Can-Fite BioPharma Ltd. - Lexicon Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - D. Western Therapeutics Institute, Inc. - Icon Bioscience, Inc. - Otsuka Holdings Co., Ltd. - Ocular Therapeutix, Inc. - Amakem NV - High Point Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/bzfhkc/ocular
Liver Cirrhosis Global Clinical Trials Review, H2 2013 is Essential Reading for those in Medical Field
M2 - Tue Jan 14, 9:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/rtmwq9/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Liver Cirrhosis Global Clinical Trials Review, H2, 2013" provides data on the Liver Cirrhosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Liver Cirrhosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Liver Cirrhosis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: - Assistance Publique - Hopitaux de Paris - Astellas Pharma Inc. - Beijing Friendship Hospital - F. Hoffmann-La Roche Ltd. - Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau - Genextra S.p.a. - Medical University of Vienna - Merck & Co., Inc. - Novartis AG - Okayama University - Otsuka Holdings Co., Ltd. - Pharmicell Co., Ltd. - Royal Prince Alfred Hospital - Sanofi - Stempeutics Research Private Limited For more information visit http://www.researchandmarkets.com/research/rt..._cirrhosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Finkelstein Thompson LLP Announces Investigation of Astex Pharmaceuticals, Inc. Buyout
Business Wire - Thu Sep 05, 10:24AM CDT
The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) ("Astex" or "the Company"
, concerning the Company's proposed acquisition by Otsuka Holdings Co., Ltd. (TYO: 45780) ("Otsuka" . Under the terms of the merger agreement, Astex shareholders will receive $8.50 in cash for each share of Astex common stock they own. The total transaction is valued at approximately $886 million. At least one analyst has set a target price of $13.00 for Astex shares.
Research and Markets: Supplement Market in the US 2012-2016 with NBTY Inc., Otsuka Holdings Co. Ltd., and Perrigo Co. Dominating
Business Wire - Thu Aug 15, 1:32PM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlh45q/supplement_market) has announced the addition of the "Supplement Market in the US 2012-2016" report to their offering.
Global Open-Angle Glaucoma Therapeutics Pipeline Review 2014 - 22 Drug Profiles from 11 Companies
M2 - Fri Sep 12, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c97xhn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Santen Pharmaceutical Co., Ltd. - Oxford BioMedica plc - Sylentis S.A. - Ono Pharmaceutical Co., Ltd. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Amakem NV Drug Profiles - tafluprost - (tafluprost timolol maleate) - latanoprostene bunod - latanoprost - OPC-1085EL - trabodenoson - SYL-040012 - RO-5093151 - latanoprost - AR-13324 - AMA-0076 - ONO-9054 - ATS-907 - DE-117 - (latanoprost dorzolamide) - LX-7101 - HPP-851 - OPA-6566 - latanoprost SR - Glaucoma-GT - ATS-8535 - Small Molecule for Glaucoma For more information visit http://www.researchandmarkets.com/research/c97xhn/openangle
Global Chronic Heart Failure Therapeutics Pipeline Review 2014 - 21 Companies & 31 Drug Profiles
M2 - Thu Sep 11, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wx7flm/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Amgen Inc. - Sanofi - Novartis AG - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Pfizer Inc. - Bayer AG - Celladon Corporation - Mesoblast Limited - Palatin Technologies, Inc. - AnGes MG, Inc. - MetrioPharm AG - Cyano Biotech GmbH - NormOxys, Inc. - Cardioxyl Pharmaceuticals, Inc. - PhaseBio Pharmaceuticals, Inc. - miRagen Therapeutics, Inc. - Fibrotech Therapeutics Pty. Ltd. - Otsuka Holdings Co., Ltd. - Zensun (Shanghai) Sci & Tech Co., Ltd. Drug Profiles - Neucardin - rivaroxaban - (sacubitril valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - ivabradine - PL-3994 - omecamtiv mecarbil - Mydicar - CXL-1020 - serelaxin (recombinant) - tolvaptan - finerenone - ivabradine - F-373280 - Stem Cell Therapy for Cardiovascular Diseases - cenderitide - beperminogene perplasmid - OXY-111A - Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - MGN-9103 - BR-5489 - FT-011 - PB-1046 - Cell Therapy for Chronic Heart Failure - SAR-296968 - RNAi Gene Therapy to Inhibit STIM1 for Cardiovascular Diseases - Peptides Inhibiting ACE for Cardiovascular and Metabolic Disorders - Vestiras For more information visit http://www.researchandmarkets.com/research/wx...onic_heart
Polycystic Kidney Disease Therapeutics Pipeline Review, H2 2014 - 21 Drug Profiles from 11 Companies
M2 - Tue Sep 09, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8mqd9t/polycystic_kidney) has announced the addition of the "Polycystic Kidney Disease - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycystic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Plexxikon Inc. - Ipsen S.A. - Pfizer Inc. - Synta Pharmaceuticals Corp. - Metabolic Solutions Development Company, LLC - IC-MedTech, Inc. - Endocyte, Inc. - ManRos Therapeutics - DiscoveryBiomed, Inc. - Otsuka Holdings Co., Ltd. - Kadmon Corporation, LLC Drug Profiles - tolvaptan - tolvaptan - lanreotide acetate - bosutinib - KD-020 - KD-019 - GLG-302 (ascorbic acid menadione) - MSDC-0160 - MSDC-0602 - EC-0371 - Small Molecule to Inhibit CKD for Polycystic Kidney Disease - Small Molecule to Inhibit Raf Kinase for Polycystic Kidney Disease - STA-2842 - Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Small Molecules to Activate AMPK for Polycystic Kidney Disease - Small Molecule to Inhibit EnaC for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Small Molecule for Polycystic Kidney Disease - Drugs Targeting CIL-1 for Genetic Disorders and Polycystic Kidney Disease - Drugs for Polycystic Kidney Disease - Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders - pyrimethamine For more information visit http://www.researchandmarkets.com/research/8m...tic_kidney
Atrial Fibrillation - Pipeline Review Report, H2 2014 - 15 Companies & 27 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xr5nbq/atrial) has announced the addition of the "Atrial Fibrillation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - AstraZeneca PLC - Isis Pharmaceuticals, Inc. - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Nissan Chemical Industries, Ltd. - Laboratoires Pierre Fabre SA - Cardiome Pharma Corp - Xention Limited - HUYA Bioscience International, LLC - Milestone Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Serodus ASA - Nyken BV - Armetheon, Inc. Drug Profiles - edoxaban tosylate - tecarfarin - vernakalant hydrochloride - bucindolol hydrochloride - vernakalant hydrochloride - ranolazine ER - XEN-D0103 - HBI-3000 - ISIS-CRPRx - (ranolazine dronedarone) - vanoxerine - F-373280 - BMS-919373 - XEN-D0101 - OPC-108459 - budiodarone - Small Molecule to Inhibit IKACh for Atrial Fibrillation - MSP-2017 - NYK-1112 - SER-102 - XEN-R0702 - GsMTx-4 - NIP-151 - Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug For Atrial Fibrillation - Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation - Small Molecules to Inhibit Voltage Gated Sodium Channel for Atrial Fibrillation For more information visit http://www.researchandmarkets.com/research/xr5nbq/atrial
Dementia Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pmw68m/dementia) has announced the addition of the "Dementia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Dementia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dementia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Dementia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Sylentis S.A. - FORUM Pharmaceuticals Inc. - Ildong Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - WhanIn Pharmaceutical Co., Ltd. - Hyundai Pharmaceutical Co., Ltd. - Summit Corporation plc - Oryzon Genomics S.A. - Intellect Neurosciences, Inc. - Intra-Cellular Therapies, Inc. - Tautatis Incorporated - Pacific Northwest Biotechnology, LLC - Otsuka Holdings Co., Ltd. - Chase Pharmaceuticals Corporation - Echo Pharmaceuticals B.V. - Chronos Therapeutics Limited - Alector LLC - ImStar Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/pmw68m/dementia
Global Glaucoma Therapeutics Market Forecasts & Opportunities, 2018
M2 - Wed Jul 02, 2:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zpvs7l/global_glaucoma) has announced the addition of the "Global Glaucoma Therapeutics Market Forecasts & Opportunities, 2018" report to their offering. Glaucoma is a disease of the eye in which fluid pressure within the eye increases. If left untreated the patient may lose vision and even become blind. The exact etiology of optic nerve damage due to glaucoma is not fully known, but involves mechanical compression and/or decreased blood flow in the optic nerve. Based on whether the cause of the disease is unknown or known, glaucoma is divided into two types, open angle and closed angle glaucoma. Five main classes of medical treatment are currently used to lower intraocular pressure: prostaglandins, beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, and fixed dose combinations. The Global Glaucoma Therapeutics market can be divided into five segments: Prostaglandins, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, and Fixed Dose Combinations. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Glaucoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Allergan Inc. - Merck & Co. Inc. - Novartis AG - Pfizer Inc. Other Prominent Vendors - Acadia Pharmaceuticals Inc. - AC Immune SA - Acorn Biomedical Inc. - Advanced Cell Technology Inc. - Aerie Pharmaceuticals Inc. - Carl Zeiss Meditec Inc. - Falcon Pharmaceuticals Ltd. - Inotek Pharmaceuticals Corp. - Lexicon Pharmaceuticals Inc. - Neurotech Pharmaceuticals Inc. - NicOx SA - Otsuka Holdings Co. Ltd. - Phytopharm plc - Santen Pharmaceuticals Co. Ltd. - Senju Pharmaceutical Co. Ltd. - SIFI SpA - Valeant Pharmaceuticals International Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Pipeline Snapshot - Rate of Incidence and Prevalence - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zp...l_glaucoma
Autism - Pipeline Review, H1 2014 - 20 Companies & 42 Drug Profiles
M2 - Fri Jun 20, 2:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ltzhjv/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - Merz Pharma GmbH & Co. KgaA - Teva Pharmaceutical Industries Limited - Avanir Pharmaceuticals, Inc. - Snowdon Inc. - Curemark, LLC - Coronado Biosciences, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Cellceutix Corporation - Heptares Therapeutics Ltd. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Naurex, Inc. - Nectid, Inc. - Mnemosyne Pharmaceuticals, Inc. - BioCrea GmbH - Saniona AB Drug Profiles - CM-AT - lurasidone hydrochloride - aripiprazole - cycloserine - fluoxetine - oxytocin - oxytocin - memantine hydrochloride - TSO - pioglitazone hydrochloride - oxytocin - oxytocin - (dextromethorphan hydrobromide quinidine sulfate) - oxytocin - oxytocin - RG-7314 - fluoxetine - fluoxetine - argipressin tannate - NU-211-01 NC-215-01 - Autologous Hematopoietic Stem Cells - glatiramer acetate - ITI-007 - Stem Cell Therapy for Central Nervous System Disorders - KM-391 - Program For Neurological Disorders - STX-110 - CN-2097 - acamprosate calcium - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome For more information visit http://www.researchandmarkets.com/research/lt...m_pipeline
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014: 16 Companies & 27 Drugs Profiled
M2 - Thu Jun 19, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhf5zs/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Nanotherapeutics, Inc. - Neurocrine Biosciences, Inc. - Addex Therapeutics - Neuralstem, Inc. - Catalyst Pharmaceutical Partners, Inc. - Humanetics Corporation - NeuroNascent, Inc. - Azevan Pharmaceuticals, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Vanda Pharmaceuticals Inc. - Marinus Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Tonix Pharmaceuticals Holding Corp. - Sage Therapeutics - Istituto Italiano di Tecnologia Drug Profiles - brexpiprazole - PRX-3140 - verucerfont - atorvastatin calcium - aprepitant - ganaxolone - iloperidone - mifepristone - oxytocin - 7-Keto - SRX-251 - SRX-246 - ITI-007 - NNI-351 - mGluR7-NAM Program For Central Nervous System Disorders - NSI-189 - cyclobenzaprine hydrochloride - S-107 - Small Molecule Targeting GABAA Receptor For Post Traumatic Stress Disorder - ZL-006 - ADX-71743 - Dihydroxyflavone - TLR-4 Antagonists for CNS Disorders - Immune Therapy For PTSD and Depression - Small Molecule Targeting GPR83 for CNS and Autoimmune Disorders - Small Molecules to Inhibit FAAH for CNS Disorders - vigabatrin For more information visit http://www.researchandmarkets.com/research/hh...ttraumatic
Global Autism Clinical Trials Review 2014
M2 - Tue Jun 17, 9:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhfbw6/autism_global) has announced the addition of the "Autism Global Clinical Trials Review, H1, 2014" report to their offering. Autism Global Clinical Trials Review, H1, 2014 provides data on the Autism clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Autism. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Autism. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Autism Speaks, Inc. - Seaside Therapeutics, LLC - Forest Laboratories, Inc. - Johnson & Johnson - Otsuka Holdings Co., Ltd. - F. Hoffmann-La Roche Ltd. - Bristol-Myers Squibb Company - Coronado Biosciences, Inc. - ZonMw - Dainippon Sumitomo Pharma Co., Ltd. - National Institute of Mental Health - Massachusetts General Hospital - Tehran University of Medical Sciences - Eunice Kennedy Shriver National Institute of Child Health and Human Development - Hugo W. Moser Research Institute at Kennedy Krieger, Inc. - Stanford University - The University of Hong Kong - University of California, Los Angeles - Mount Sinai Hospital - University of California, San Francisco For more information visit http://www.researchandmarkets.com/research/vh...ism_global
Ocular Hypertension - Pipeline Review, H1 2014
M2 - Mon Jun 16, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bzfhkc/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Alcon, Inc. - F. Hoffmann-La Roche Ltd. - Bausch & Lomb Incorporated - Allergan, Inc. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. - Kowa Company, Ltd. - Ono Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Can-Fite BioPharma Ltd. - Lexicon Pharmaceuticals, Inc. - Laboratoires Thea S.A. - Asahi Kasei Pharma Corp. - Inotek Pharmaceuticals Corporation - Aerie Pharmaceuticals, Inc. - D. Western Therapeutics Institute, Inc. - Icon Bioscience, Inc. - Otsuka Holdings Co., Ltd. - Ocular Therapeutix, Inc. - Amakem NV - High Point Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/bzfhkc/ocular
Liver Cirrhosis Global Clinical Trials Review, H2 2013 is Essential Reading for those in Medical Field
M2 - Tue Jan 14, 9:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/rtmwq9/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Liver Cirrhosis Global Clinical Trials Review, H2, 2013" provides data on the Liver Cirrhosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Liver Cirrhosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Liver Cirrhosis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: - Assistance Publique - Hopitaux de Paris - Astellas Pharma Inc. - Beijing Friendship Hospital - F. Hoffmann-La Roche Ltd. - Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau - Genextra S.p.a. - Medical University of Vienna - Merck & Co., Inc. - Novartis AG - Okayama University - Otsuka Holdings Co., Ltd. - Pharmicell Co., Ltd. - Royal Prince Alfred Hospital - Sanofi - Stempeutics Research Private Limited For more information visit http://www.researchandmarkets.com/research/rt..._cirrhosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Finkelstein Thompson LLP Announces Investigation of Astex Pharmaceuticals, Inc. Buyout
Business Wire - Thu Sep 05, 10:24AM CDT
The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) ("Astex" or "the Company"
, concerning the Company's proposed acquisition by Otsuka Holdings Co., Ltd. (TYO: 45780) ("Otsuka" . Under the terms of the merger agreement, Astex shareholders will receive $8.50 in cash for each share of Astex common stock they own. The total transaction is valued at approximately $886 million. At least one analyst has set a target price of $13.00 for Astex shares. Research and Markets: Supplement Market in the US 2012-2016 with NBTY Inc., Otsuka Holdings Co. Ltd., and Perrigo Co. Dominating
Business Wire - Thu Aug 15, 1:32PM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlh45q/supplement_market) has announced the addition of the "Supplement Market in the US 2012-2016" report to their offering.
